Abstract-Poly ADP-ribose Polymerase 1 (PARP1) is an important enzyme that is involved in DNA repair, replication, and transcription. Prospective anticancer drug gossypol inhibits human PARP1, but the mechanism of inhibition remains unknown. It has been shown previously that gossypol interacts with purified BRCA1 C-terminus (BRCT) domain in vitro. However, it remained unclear whether gossypol inhibits PARP1 through the BRCT domain in the context of full-length protein. Here, we report that the BRCT domain within the full-length PARP1 protein is not required for the inhibition of catalytic activity of PARP1 by gossypol. Our results, obtained using a series of PARP1 mutations and H4-dependent pathway of PARP1 activation, also show that none of the zinc fingers or other DNA binding domains of PARP1 are involved in the inhibition of the PARP1 catalytic activity by gossypol. Thus, the likely candidate target(s) for gossypol action are the other domains of PARP1, or the interdomain linkers.
INTRODUCTION
Proteins of poly(ADP-ribose) polymerases (PARP) are nuclear and cytoplasmic enzymes that cleave NAD+ to nicotinamide and ADP-ribose with the formation of long and branched ADP-ribose polymers on target proteins, including topoisomerases, histones, and PARP [1] . Except for histones, poly(ADP-ribose) polymerase 1 (PARP1) is the most common nuclear protein (1-2 million molecules per cell). It is responsible for the production of approximately 90% of ADP-ribose polymers in the cell [2, 3] . Poly(ADP-ribosylation) is a regulatory mechanism associated with cell-cycle, replication, cell aging and death, remodeling of chromatin structure, gene transcription, and other cellular functions [4, 5] . PARP1 protein in mice and humans ( Fig. 1a ; molecular weight of 116 kDa) has a modular structure with three major functional regions: the DNA-binding domain, the catalytic domain, and domain associated with automodification [6, 7] . The DNA binding domain comprises three zinc fingers (Zn1, Zn2, Zn3), which bind to the single-stranded or double-stranded breaks in the DNA chain as well as with to the linker DNA in the chromatin [8] . The third zinc finger (Zn3) identified in the 250-350 aa region is unique and different in structure and function from Zn1 and Zn2 [9, 10] . Zn3 is not only involved in the activation of PARP in response to DNA damage but also plays a role in chromatin compaction [11] . Biochemical studies demonstrate that Zn3 serves as a link between the DNAbinding domain and WGR-domain of the automodification region. This interaction results in a stimulation of the catalytic activity of PARP1 [12] . The automodification region is located in the central part of PARP1 and contains the BRCT-(Breast canceR type 1 C-Terminus) domain and WGR-enriched residues Trp (W), Gly (G), and Arg (R). BRCT provides for protein-protein interactions, and it is usually present in proteins involved in DNA repair and regulation of the cell cycle [13] . BRCT domain is required for PARP1 interaction with different protein partners, including XRCC1 [14] , hUbc9 [15] , histones [16] , oct-1 [17] , and YY1 [18] . Automodification (poly(ADP-ribosylation) of PARP1) can regulate the interaction between PARP1 and its partners. BRCTdomain is a potential target for the action of a variety of small molecule inhibitors that can disrupt proteinprotein interactions [19] . WGR motif is involved in the formation of inter-domain contacts. The catalytic region of PARP1 contains two domains: the helical domain (HD) and the (ADP-ribosyl)transferase. As a rule, the catalytic domain is the target of PARP1 inhibitors. PARP1 inhibitors are considered as promising antitumor agents [20] acting as chemotherapy and radiation sensitizers in conventional therapies of malignant tumors. Furthermore, PARP1 inhibitors can be used as stand-alone medications against
MOLECULAR BIOLOGY
tumors, in which certain DNA repair pathways are disrupted. PARP1 expression is elevated in melanoma, lung and breast cancer, and other neoplastic diseases. This increased expression level is considered to be predictive and associated with inferior survival prognosis.
Almost all existing inhibitors of PARP1 are designed to bind to the catalytic domain of PARP1 and compete with NAD+. It should be noted that the NAD+ is a cofactor that cooperates with a number of enzymes involved in many cellular processes. Therefore, competition with NAD+ can lead to high toxicity. This is the main reason for why many PARP1 inhibitors have failed in the clinical trials and have been taken out of testing already at trial stages I and II. Compound olaparib (commercialized under the name Lynparza™ by AstraZeneca) is among the few PARP1 inhibitors that have reached stage III trials and have been approved both by the European Commission and the US Food and Drug Administration for use in the clinic. However, due to a number of side effects, the use of olaparib is limited to female patients with a diagnosis of "ovarian cancer with BRCA mutation" sensitive to platinum drugs. Since inhibitors targeting the catalytic domain of PARP1 exhibit high toxicity, a promising approach to the creation of novel less toxic inhibitors of PARP1 consists in identifying active compounds directed to other functional domains of the PARP1 protein.
Gossypol molecule has been shown to bind PARP1 and inhibit its activity [19] . Gossypol is a natural polyphenol from cottonseed, which possesses multifunctional properties, in particular: antiviral, antimicrobial, antiprotozoal, antioxidant, and antitumor activity [21] . In the study by Na Z. et al. [19] , the authors suggested that the mechanism of inhibitory action of gossypol on PARP1 is not associated with the inhibition of enzyme active site but with gossypol interaction simultaneously with BRCT-domains of two PARP1 molecules. This results in a crosslinking of two enzyme molecules with consequent fixation of conformation of the two PARP1 domains, which prevents implementation of the catalytic activity. However, the authors of this study did not examine the role of BRCT-domain in the context of a full-length PARP1 protein. Thus, many assumptions resulting from this study appear controversial. To clarify these questions, in this study, we examined a series of PARP1 mutants to determine the potential targets of gossypol action.
MATERIALS AND METHODS
Full length PARP1 and its mutants for Zn3 and BRCT domains were obtained as described previously [22] . The scheme of used proteins and mutants is presented in Fig. 1a . Single-stranded DNA (Sigma, United States) was sonicated for 1 h to introduce brakes. DNA with breaks was used to activate PARP1. For immunoblotting, we used monoclonal antibody 10H (ANTI-PAR, Tulip Biolabs). Histone H4 was prepared as described previously [23] . We used gossypol (Santa Cruz Biotechnology, United States, CAS 303-45-7) and olaparib (Santa Cruz Biotechnology, United States, CAS 763113-22-0) (chemical formulas are shown in Fig. 1b) . PARP1 activation was performed as follows: 1 pM of PARP1 protein was mixed with 100 ng of ssDNA, or 1 μg of histone H4, in the presence of 1 μM of NAD+ (alone or in combination with a 10 pM of an inhibitor, gossypol or olaparib) in a total volume of 15 μL. Reaction mixture was incubated for 40 min, then stopped by adding 5λ of 4X. Evaluation of poly(ADP-ribosylation) of PARP1 in the presence of inhibitors was performed by immunoblotting. First, samples in 4x in Laemmli buffer were separated in 4-12% NuPAGE gels in MOPS (3-[N-Morpholino] propanesulfonic acid) buffer (Invitrogen, United States) for 45 min. Then, samples were transferred to PVDF membrane at 4°C for 2 h at 240 mA. Membrane was blocked with PBS-Tween containing 5% dry milk for 1 h at room temperature, washed, then, incubated for 1 h with 10 mL of 10H ANTI-PAR antibodies (diluted 1 : 2000 in PBS-Tween containing 5% dry milk), washed three times for 10 min in PBSTween, and incubated with 10 mL goat antimouse secondary antibodies conjugated to horseradish peroxidase (diluted 1 : 5000 in PBS-Tween, containing 5% dry milk) for 1 h, and washed three times for 10 min in PBS-Tween. Products of immunoblotting were revealed using ECL-reagent (Sigma, United States).
RESULTS
Analysis of the effect of olaparib and gossypol (Fig.  1c) on the catalytic activity PARP1 showed that these substances inhibit the reaction of PAR poly(ADPribosylation) to varying degrees: olaparib blocks it completely, while gossypol blocks it only partially (Figs. 1c, 1d) . To evaluate the role of the BRCT domain in the inhibition by the tested compounds, we used PARP1 mutant containing a complete deletion of the BRCT domain (ΔBRCT) (Fig. 1a, structure 3) . Despite the fact that BRCT domain is part of the PARP1 protein automodification region, its removal does not completely eliminate the protein ability for automodification (Fig. 1b, lane 4) . We found that olaparib completely inhibited automodification of ΔBRCT protein and gossypol only partially inhibited it (Fig. 1e) . Therefore, the two substances have similar activity against both native and mutant PARP1, which indicates that deletion of the BRCT-domain does not affect the activity of inhibitors. In the case of olaparib that targets the catalytic site of the enzyme, this result was expected. However, for gossypol, whose target can be the BRCT-domain as described in [19] , the result was unexpected.
Further search for the targets of gossypol action was conducted using a mutant for the Zn3-domain (Fig. 1a, design 2) . This region is also involved in the formation of the cross-domain interactions within PARP1 protein, and gossypol may interfere with such interactions. In this study, we used a Zn3 mutant with two substitutions, L348D and V350D, in the Zn3 domain of PARP1, important for the compaction of chromatin [11] . Our results showed that mutant protein is functionally active (Fig. 1b) , and PAR-activity was inhibited in the presence of gossypol in a similar manner (Fig. 1e, lanes 6, 7) . Thus, neither the BRCT or Zn3 domains are targets of gossypol action.
In the course of the two previous sets of experiments, PARP1 was activated by mixing with nicked DNA. Then, we compared the ability of gossypol to inhibit PARP1 activation caused either by DNA, or by H4-dependent activation (Fig. 1e, lanes 4, 8) . We found that gossypol inactivates both DNA-dependent and H4-dependent automodification of PARP1, with a more pronounced effect in the latter case. Since none of the PARP1 zinc fingers are involved in H4-dependent PARP1 automodification, we conclude that zinc finger domains are not required for gossypol action.
DISCUSSION
Results of previous studies led to the development of a hypothesis that gossypol selectively binds to the BRCT-domains of two PARP1 molecules, thereby causing dimerization of the protein [19] . Such protein-protein crosslinking by gossypol "fixes" PARP1 in a stable conformation, and precludes conformational changes within its domains leading to the loss of PARP1 catalytic activity. A number of studies indicate that activation of PARP1 requires a conformational change that would release the pocket of the catalytic center from the "blocking" domain [12, 24] . This important assumption of the existence of a PARP1 inhibitor, whose effect is not associated with inhibition of catalytic activity, could lay the groundwork for the identification of a new category of the inhibitory compounds. To test our hypothesis in respect to the gossypol recognition of the BRCT-domain of PARP1, we used a series of BRCT mutants. In our experiments, we did not detect any difference between the Within the scope of this work, we investigated the effects of gossypol in mutants for only four domains of PARP1: three zinc fingers and BRCT. Other PARP1 regions remain unexplored, for example, the WGR domain. It is also possible that gossypol acts not on a particular domain but at the interface of two or more domains. PARP1 domains are not fully active separately, and they often must work together to carry out a specific function. For example, Zn3 and WGR domains act cooperatively, first, to promote binding to DNA and, then, to cause conformational rearrangements of the PARP1 protein and stimulation of the catalytic domain [12] . The experimental approach proposed in this paper enables us to explore a variety of substances whose inhibitory activity is based on the binding outside of the catalytic domain of PARP1. This study contributes to the better understanding of the complex mechanism of PARP activation and to further the searches of therapeutic substances-inhibitors of PARP1 with new properties.
